目的： 分析重组人Krüppel类因子4（Krüppel-like factors 4，KLF4）基因在肝癌HepG2细胞中对化疗和光动力治疗的调节作用。 方法： 构建人KLF4慢病毒pWPTS-KLF4载体，应用RT-PCR、Western blotting检测pWPTS-KLF4感染后HepG2细胞中KLF4 mRNA和蛋白的表达，MTT实验检测HepG2细胞对顺铂、环磷酰胺或氟尿嘧啶耐受性的变化以及对光动力治疗敏感性的变化，罗丹明123染色检测HepG2细胞线粒体膜电位的变化。 结果： 成功构建慢病毒pWPTS-KLF4载体。顺铂、环磷酰胺或氟尿嘧啶处理HepG2细胞72 h后，pWPTS-KLF4感染组HepG2细胞存活率较对照组明显增高\[（43.43±4.78）% vs (18.09±102)%；(110.51±4.58)% vs (75.23±5.92)%；(34.55±2.93)% vs (19.16±1.32)%，P<0.01\]。光敏剂艾拉介导的光动力治疗后24 h，pWPTS-KLF4感染组HepG2细胞存活率较对照组明显减少\[（37.16±3.26）% vs (57.24±8.01)%，P<0.01\]，细胞的线粒体膜电位明显降低。 结论： 重组人KLF4可以提高HepG2细胞化疗耐受性，增加光动力治疗敏感性。

Objective To explore the regulatory effects of Krüppel-like factors 4 (KLF4) on chemotherapy and photodynamic therapy on HepG2 cells. Methods: Lentiviral pWPTS-KLF4 vector containing human KLF4 was constructed. The expression of KLF4 mRNA and protein in HepG2 cells after pWPTS-KLF4 infection was analyzed by RT-PCR and Western blotting; the tolerance of HepG2 cells to cisplatin, cyclophosphamide and fluorouracil and the sensitivity of HepG2 cells to photodynamic therapy were evaluated by MTT assay; the change of mitochondrial membrane potential in HepG2 cells was examined by Rhodamine 123 staining. Results: Lentiviral pWPTS-KLF4 vector was successfully constructed. Treated with cisplatin, cyclophosphamide or fluorouracil for 72 h, the vialble HepG2 cells were significantly increased after pWPTS-KLF4 infection (\[43.43±4.78\]% vs \[18.09±1.02\]%；\[110.51±4.58\]% vs \[75.23±592\]%；\[34.55±293\]% vs \[19.16±1.32\]%, P<0.01); Treated with ALA mediated photodynamic therapy for 24 h, vialble HepG2 cells were significantly decreased after pWPTS-KLF4 infection (\[37.16±3.26\]% vs \[57.24±801\]%, P<0.01), and mitochondrial membrane potential was significantly decreased. Conclusion: Recombinant human KLF4 can increase the tolerance of HepG2 cells to chemotherapy and the sensitivity of HepG2 cells to photodynamic therapy.

天津市自然科学基金项目资助（No.10JCYBJC11500）